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Contributory Anti-Inflammatory Effects of Mesenchymal Stem
Cells, Not Conditioned Media, On Ovalbumin-Induced
Asthmatic Changes in Male Rats
Mahdi Ahmadi,1 Reza Rahbarghazi,2 Sina Soltani,2 Mohammad Reza Aslani,1 and Rana Keyhanmanesh 3,4
ABSTRACT—Our aim in selecting an appropriate cell fraction and conditioned media (CM) was to
achieve the suitable candidate for ameliorating long-term chronic asthmatic changes of respiratory tract.
Thirty-six rats were classified into healthy and sensitized groups, which were further divided into three
subgroups; rats received systemically 50 μl volume of PBS, CM, or 2 × 106 rat bone marrow-derived
mesenchymal stem cells (rBMMSCs). Tracheal responsiveness (TR), immunologic responses, and
recruitment of rBMMSCs into the lungs were evaluated. A high degree of TR and total WBC and
percentages of eosinophils and neutrophils was significantly recorded in all sensitized groups rather than
of controls (p < 0.001 to p < 0.05). Concurrently, a significant improvement of TR and eosinophil and
neutrophil return toward normal levels was evident in sensitized rats receiving cells as compared to
parallel asthmatic animals. Flow cytometric monitoring of lymphocyte subpopulation revealed a
decrease in the number of CD3+CD4+ and concurrent increase in CD3+CD8+ in all sensitized rats as
compared to control (p < 0.001 to p < 0.05). Noticeably, no significant modulatory effects of either cell
or CM administration were achieved on the CD3+CD4+ and CD3+CD8+ populations in non-asthmatic
rats. Corroborating our results, the number of CD3+CD4+ tended to increase (p < 0.05) which coincided
with a decreased manner of CD3+CD8+ populations as compared to other asthmatic groups (p < 0.01 to
p < 0.05).Moreover, stem cells could efficiently transmigrate to the lung parenchyma, albeit the dynamic
of asthmatic changes stimulated the rate of recruited cells. Our study shed light on superior effects of
mesenchymal stem cells, but not CM, in attenuating chronic asthmatic changes in the model of rat.
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INTRODUCTION
Asthma is conceived as a chronic lung disorder with a
very high socioeconomic burden, characterized by
reversible obstruction, hyper-responsiveness, aberrant
remodeling, and noticeable airway inflammation [1, 2].
Based on previous experiments, numerous inflammatory
cells from different lineages such as eosinophils, T cells,
neutrophils, macrophages, and mast cells could infiltrate to
inflamed niche and initiate a sequential stepwise of airway
inflammation exerted via secretion of mediators [3, 4].
Asthma per se is not curable by any current drugs and
convenient strategies, including anti-inflammatory agents
and potent bronchodilators, which are used to suppress or
alleviate asthma-related symptoms, albeit some relevant
side effects impose to affected individuals [5–7]. Since
the prominent and problematic characteristic of asthma is
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well established by the inflammation of airway, the main
solution for treatment of this disorder is focused to
control the severity and period of the aforementioned
process [7, 8].
Of note, new emerging policies have been un-
dertaken not only to sedate asthma-related complica-
tions but also to trigger the regeneration of chronic
changes [9–11]. In line with this thought, different
stem cells (SCs), particularly mesenchymal stem cells
(MSCs), are touted as a population of multi-potent
cells, which are found in all adult tissues constituting
approximately less than 0.01 % of total cells [12]. In
addition to generally defined inherent plastic adher-
ent, self-renewal properties and fibroblast-like appear-
ance, they are able to differentiate into a variety of
mesenchymal lineages under appropriate controlled
conditions [13]. Until the present time, there is con-
troversy against the role of MSCs on the inflamma-
tion procedure. For instance, Abreu et al. previously
showed a remarkable reduction in immune response
coincided by the decrement of collagen fiber content
and eosinophil infiltration rate in the chronic murine
model of asthma [10]. The cell administration imme-
diately after sensitization resulted in appropriate im-
mune system responses with a shift in T helper 2 to
1 phenotype [14]. In contrast, Trzil and colleagues
already affirmed the lack of attenuating properties of
adipose-derived MSCs in a feline model of chronic
allergic asthma [15].
Two main contributory effects of MSCs, includ-
ing paracrine activity and trans-differentiation capac-
ity, have been previously documented in target tis-
sues [16]. With regard to limiting factors related with
SC administration, the lack of total costs, immuno-
logic reactions, tumorigenicity, and waiting time for
cellular expansion makes paracrine soluble factors
more suitable for regeneration of target tissue [17].
As far as we know, there is no experiment to
assess both juxtacrine and paracrine therapeutic
effects of bone marrow-derived MSCs monoculture
and MSC-derived conditioned media (CM) separately
on immunologic response and CD4+ and CD8+ cells
as a rat model of asthma. Our aim in selecting an
appropriate cell fraction and CM was to achieve the
suitable candidate for ameliorating long-term chronic
asthmatic changes of respiratory tract and to decipher
fundamental mechanisms of the inflammation in
allergic asthma pathophysiology.
MATERIALS AND METHODS
Animal Ethics
All procedure phases of the current experiment
were identical to the published guideline of The Care
and Use of Laboratory Animals (NIH Publication No.
85-23, revised 1996) and approved by the Animal
Care Committee of Tabriz University of Medical
Sciences (No. TBZMED.REC.1394.386).
Cell Isolation and Expansion Procedure
Rat bone marrow-derived mesenchymal stem
cells (rBMMSCs) were isolated and expanded as
previously described by different authorities [18]. In
brief, rats were humanely euthanized by an overdose
combination of xylazine and ketamine followed by
complete removal of femurs. Afterwards, the epiphy-
sis part of each femur was cut and medullary com-
ponents immediately flushed out by PBS solution
containing 2 % fetal bovine serum (FBS; Gibco,
USA). Next, bone marrow mononuclear cells were
isolated and enriched by Ficoll (Sigma, USA) gradi-
ent centrifugation at 400×g for 20 min and then
washed twice by PBS solution. The cellular pellet
was resuspended in Dulbecco’s modified Eagle’s me-
dium low glucose (DMEM/LG; Gibco, USA) con-
taining 20 % FBS, 100 U/ml penicillin, and
100 mg/ml streptomycin (Biosera, UK). Ultimately,
an initial seeding density of 1 × 105 cells was plated
in each square centimeter of six-well plates (SPL).
The exhausted medium was further replenished every
4 days and passaged after reaching 70–80 % conflu-
ency. The cells at third passage were subjected to
current experiment.
Immunophenotyping Characterization of Isolated
rBMMSCs
To further confirm the stemness characters of
isolated cells, rBMMSCs after third passage were
immunophenotypically assessed by BD FACSCalibur
flow cytometer (USA) [19]. A panel of antibodies
directed against stem-related markers, including
FITC-conjugated anti-CD133 (eBioscience, USA),
CD44 (eBioscience, USA), and CD34 (eBioscience,
USA) as well as PE-conjugated anti-CD31 (eBio-
science, USA), was provided. In addition, relevant
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isotopes control antibodies were also used to normal-
ize non-specific background and binding. Briefly, the
cells were trypsinized by 0.025 % Trypsin-EDTA
solution (Gibco, USA), washed twice by PBS, and
blocked by 1 % BSA (Sigma, USA) for 15 min.
Thereafter, recommended antibody concentration for
each abovementioned marker was added into 100 μl
of PBS containing 5 × 105 cells, incubated for 30 min
at RT, and then washed by PBS. Ultimately, cells
were subjected to flow cytometry system, and final
output data were analyzed by Flow Jo software
ver.7.6.1.
rBMMSCs Labeling with CM-Dil
To monitor the recruitment and homing of rBMMSCs
into lungs of sensitized rats, the cells were trypsinized and
labeled with 2 μM Cell Tracker™ CM-Dil for 20 min at
37 °C (Catalog No. C-7000; Molecular Probes, Invitrogen,
USA). Thereafter, a final volume of 50 μl PBS containing
2 × 106 CM-Dil pre-labeled cells per rat was gently admin-
istrated intravenously.
Conditioned Media (CM) Harvesting
To address the possible role of rBMMSCs in the
alleviation of ovalbumin-induced asthma in rats via a
paracrine manner, the CM produced by rBMMSCs
was prepared. In short, after 70–80 % confluency,
the DMEM/LG supplemented with 10 % FBS was
discarded, washed three times with PBS, and incu-
bated with DMEM/LG-free FBS for 72 h [20]. Next,
the supernatant was collected, centrifuged at 400×g
for 5 min, filtered by 0.20-μm-pore syringe filter,
and further concentrated approximately 50-fold by
centrifuge filter tubes with molecular weight cut-offs
at 4 kDa (catalog no. 003099.125; Eppendorf, Ger-
many). Finally, 50 μl per case of concentrated CM
was injected intravenously [10].
Animal Sensitization and Animal Groups
Forty mature male Wistar rats, weighing 200–250 g,
were enrolled to the current experiment. The animals were
kept in PVC cages under 12:12 light/dark cycle at 20 ±
2 °C with free access to standard rat chow and water. After
acclimatization, four rats were randomly selected for ex-
traction and characterization of rBMMSCs prior to the
sensitization procedure. The remaining 36 rats were
randomly subdivided into six groups (n = 6 for each group)
as follows:
1. Healthy rats only received 50 μl PBS (C)
2. Healthy rats received 50 μl CM (CSV)
3. Healthy rats 50 μl PBS containing 2 × 106 rBMMSCs
(CCV)
4. Sensitized rats only received 50 μl PBS (S)
5. Sensitized rats received 50 μl CM (SSV)
6. Sensitized rats received 50 μl PBS containing 2 × 106
rBMMSCs (SCV)
In the sensitized groups, rats were challenged with
ovalbumin (OA) over a period of 32 ± 1 days according to
the method described previously [21]. Briefly, rats were
injected with 1 mg ovalbumin (Sigma-Aldrich, USA) and
200 mg aluminum hydroxide, dissolved in 1 ml saline,
intraperitoneally on the first and eighth days. From the
14th day, the sensitized rats were exposed to an aerosol
of 4 % ovalbumin, created by nebulizer (CX3; Omron Co.,
Netherlands), for 18 ± 1 consecutive days, for 5 min per
day. This exposure was performed in a closed box with
dimensions 30 × 20 × 20 cm3 (Fig. 1). In healthy parallel
rats, saline was administered instead of ovalbumin in the
samemanner [2]. One day after sensitization, the sensitized
rats were subjected to the experimental procedure of cell or
CM administration that was separately injected through the
left femoral vein. Calling attention, many authorities
acclaimed that the respiratory responses directed to
ovalbumin-induced sensitization last over a course of
2 weeks [22, 23].
Tissue Sample Preparation
Two weeks after administration, all animals were
anesthetized by the combination of ketamine (75 mg/kg)
and xylazine (3mg/kg) intraperitoneally [24]. Shortly, after
opening the chest, their tracheas were gently removed and
subsequently sliced longitudinally into two equal pieces of
5 mm. Thereafter, each slice was horizontally mounted
between two stainless steel hooks. The lower hook was
anchored at the base of the organ bath (Schuler organ bath
type 809, Germany) and the next one attached to an iso-
metric transducer (MLT02020, AD Instruments, Spain)
[25]. The organ bath was fully filled with 20 ml of Krebs
solution and oxygenated consistently with 95 % O2 and
5 % CO2 gas mixture at 37 °C. To establish a steady
spontaneous tone level, prior to drug additions, a passive
tension of 1 g was also applied for at least 60 min.
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Throughout this period, the exhausted Krebs solution was
replenished every 15 min. The changes in isometric force
were measured by a transducer coupled to a Power Lab
(ML-750, 4 channel recorder; March-Hugstetten, Ger-
many), amplified by an amplifier, and final raw data was
interpreted [26].
The Assessment of Tracheal Responsiveness to
Methacholine
In each measurement, a dose-dependent response
curve of methacholine-induced contraction of a tracheal
piece was constructed. In short, cumulative concentrations
(10−7 to 10−3 mM) of methacholine were added
consecutively to the bath chamber every 3 min, and the
response elicited by each additional dose was recorded
after the contraction of the tracheal smooth muscle had
plateaued. To construct the curve, the percentage of
contraction caused by each methacholine concentration in
proportion to the maximum contraction obtained by its
final concentration was plotted against log concentration
of methacholine. Thereafter, EC50 as the effective
concentration of drug generating 50 % of the maximal
response was expressed in each experiment using
methacholine response curves. The contractility response
to 10 μM methacholine was also measured as the
magnitude of tracheal contraction [27].
Lung Lavage Fluid (LLF) and its Total and Differential
Leukocyte Count
After removing the trachea, the lavage was gently
performed using 1 ml of normal saline with ten times
repetition via a catheter which was inserted into the remain-
ing part of the trachea. A volume of 0.5 ml of collected
fluid was stained with the same volume of Turk solution
(1:1 dilution), and total leukocytes were counted micro-
scopically in a Neubauer chamber. Turk solution consisted
of 1 ml of glacial acetic acid, 1 ml of Gentian violet
solution 1 %, and 100 ml distilled water.
The rest of the lung fluid was centrifuged at 2500×g
for 10 min at 4 °C. The supernatant was discarded, and the
thin smear of cells was prepared and stained with Wright-
Giemsa stain. Finally, according to cellular morphological
characteristics, the percentage of differential leukocytes
was determined using a light microscope [28].
Total and Differential White Blood Cell Count
Prior to tracheal responsiveness or bronchoalveolar
lavage, 5 ml blood sample was immediately withdrawn via
the abdominal aorta. The blood samples were diluted 1 in
20 with Thoma’s solution and counted in duplicate in a
Neubauer chamber. To clearly differentiate the cell type,
smears on glass slides were stained by Wright-Giemsa
solution, then the percentage of each type of leukocyte
was calculated under the light microscope [8].
CD3+CD4+ and CD3+CD8+ Populations in the Circulatory
System
To clearly understand whether the administration of
marrow-derived MSCs or intravenous injection of CM
could alter the percentage of CD4 or CD8 cells, the blood
samples from each group were collected and submitted to
flow cytometry assay. In brief, an equal diluted blood with
PBS (1:1) was overlaid on the same volume of Ficoll
(Sigma, USA) and centrifuged at 400×g for 30 min at
4 °C. After washing the harvested mononuclear cell three
times with PBS, a panel of antibodies against T lympho-
cyte sub-population, including FITC-conjugated mouse
anti-rat CD3 (eBioscience, USA), PE-conjugated mouse
anti-rat CD4 (eBioscience, USA), and CD8 (eBioscience,
USA), was used. Cells were incubated with recommended
concentration of antibodies for 30 min. Finally, cells were
subjected to flow cytometry (BD FACSCalibur, USA) and
final output data were analyzed by Flow Jo software
ver.7.6.1.
Immunofluorescence Assay
To confirm the presence of injected cells, the isolated
pulmonary tissues were embedded in tissue freezing media
at the end stage of the experimental procedure, snap-
frozen, and sectioned at 5 μm using Cryostat apparatus
[19]. After thawing the sections at RT, slides were washed
twice (5 min each) and stained with 4′, 6-diamidino-2-
OA  
(ip) 
OA  
(ip) OA 
(Nebulized)
rBMMSCs 
CM 
(IV) Sacrificing
1 8 14 32 33 48 14 days 
Procedure 
Time (day) 
18 days 
Fig. 1. Flowchart and timeline of the study design. OA ovalbumin, ip intraperitoneally.
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phenylindol (DAPI, 1 μg/ml, catalog # D9542; Sigma-
Aldrich, USA) for nuclear counterstaining.
Statistical Analysis
All results were presented as mean ± SEM. The data
of three sensitized groups were compared with C
group using one-way analysis of variance (ANOVA)
with Tukey-Kramer post hoc test. Also, the data of
the SCV group were compared with the SSV group
using the unpaired t test. We considered statistical
significance at p <0.05.
RESULTS
Immunophenotypical assessment of rBMMSCs after
the third passage confirmed the stemness characters of
isolated cells. Moreover, histograms showed cells positive-
ly stained with CD133 and CD44 (Fig. 2).
Tracheal Response to Methacholine
The concentration-response curve to methacholine
was shifted leftward in all of the sensitized groups in
comparison with the control group (C), whereas the curve
of the SCV group showed a rightward shift in comparison
with the cell- and CM-free sensitized animals (S). The
curve of the SSV group was more similar to group S, and
the curves of the CCVand CSV groups were more similar
to group C (Fig. 3).
The mean value of EC50 in the tracheal pieces of S
(0.75 ± 0.01 μM), SSV (0.78 ± 0.01 μM), and SCV (0.82
± 0.008 μM) groups were significantly lower than group C
(3.6 ± 0.07 μM, p < 0.001); however, the mean value of
EC50 in a tracheal piece of the SCV group showed signif-
icant improvement in comparison with group S (p < 0.01,
Fig. 4). Mean value of EC50 in the tracheal piece of the
SSV group was significantly lower than of the SCV group
(p < 0.05).
The contractility response of a tracheal piece to meth-
acholine in all of the sensitized groups was significantly
higher than group C (p < 0.001 for S and SSV groups and
p < 0.05 for SCV). The contractility response in the SCV
group was significantly lower than group S (p < 0.01).
Moreover, the contractility response of group SSV was
significantly greater than that of the SCV group (p < 0.01,
Fig. 5).
Total White Blood Cell (WBC) Count
The mean value of total WBC in groups S (11,916 ±
166.17), SSV (11,833 ± 125.61), and SCV (11,016 ±
Fig. 2. Phase contrast micrographs of the confluent monolayer of rBMMSCs (passage 3) (a). Cultured rBMMSCs’ phenotypic characterization (b). The
expression of both positive and negativemarkers related to BMMSCswas assessed by flow cytometry analysis. Histograms show cells positively stainedwith
CD133 and CD44.
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153.66) were increased significantly in comparison with
group C (5116 ± 94.57, p < 0.001 for all). The mean value
of total WBC in the SCV group decreased significantly
compared to S and SSV groups (p < 0.01, Table 1).
Differential Percentages of White Blood Cell (WBC)
Count
The percentage of eosinophil in all sensitized groups
was significantly higher than group C (p < 0.001 to
p < 0.01). There was a significant decrease in eosinophil
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percentage of the SCV group in comparison with the S and
SSV groups (p < 0.05).
The percentage of neutrophil in the S and SSV groups
was significantly higher than group C (p < 0.05). There
was a non-significant decrease in neutrophil percentage
of the SCV group in comparison with the S group, al-
though it was non-significantly more than in the control.
The lymphocyte percentage in all sensitized groups
was significantly lower than group C (p < 0.01 to p < 0.05).
However, there was a significant increase in lymphocyte
count of SCV group in comparison with the S group
(p < 0.05).
The percentage of monocyte in all sensitized
groups was significantly lower than group C (p < 0.01
to p < 0.05). There was a non-significant increase in
monocyte percentage of the SCV group in comparison
with the S group, but in the SSV group, it was non-
significantly lower than the S group (Table 1).
Total Leukocyte Count in Lung Lavage Fluid (LLF)
The mean value of total leukocyte in LLF in groups S
(100 ± 2.58), SSV (97.5 ± 2.50), and SCV (90.84.14 ± 1.53)
were significantly higher than that of group C (32.5 ± 2.14,
p < 0.001 for all). The mean value of total leukocyte in the
SCV group decreased significantly compared to group S and
SSV (p < 0.05, Table 2).
Differential Leukocyte Percentage in Lung Lavage
Fluid (LLF)
The percentages of eosinophil and neutrophil in all
sensitized groups were significantly higher than group C
(p < 0.001 to p < 0.05). There was a significant decrease in
eosinophil and neutrophil percentages of the SCV group in
comparison with the S and SSV groups (p < 0.05). How-
ever, the neutrophil percentage in the SSV group was non-
significantly increased compared to the S group.
The percentage lymphocyte in all sensitized groups was
significantly lower than group C (p< 0.01 to p< 0.05). There
was a significant increase in lymphocyte percentage of SCV
group in comparison with S and SSV groups (p < 0.05).
The percentage of monocyte in S and SSV groups
was significantly lower than group C (p < 0.05). There was
a significant increase in monocyte count of the SCV group
in comparison with the S group (p < 0.05).
The percentage of basophil in all sensitized groups
was significantly higher than group C (p < 0.05). There
was a non-significant decrease in basophil percentage of
the SCV group in comparison with the S group (Table 2).
Administration of MSCs Could Repopulate the CD4+
and CD8+ Cells in Asthmatic Rats
Based on our results, no significant modulatory
effects of either cell administration or CM injection were
achieved on the population of CD3+CD4+ and CD3+CD8+
cells in non-asthmatic rats. In contrast, the percentages of
CD3+CD4+ cells in all sensitized groups significantly
decreased as compared with group C (p < 0.001) while
CD3+CD8+ cells increased (p < 0.001 to p < 0.05). Of
note, the levels of CD3+CD4+ and CD3+CD8+ cells in
asthmatic rats that received MSCs showed a drastic
difference in comparison with S and SSV groups. In
detail, the percentages of CD3+CD4+ increased
significantly (p < 0.05), whereas CD3+CD8+ cells
Table 1. Total and Differential Percentage of White Blood Cell (WBC) Count in C (Control Group), CSV (Healthy Animals Received CM), CCV (Healthy
Animals Received rBMMSCs), S (Sensitized Animals), SSV (Sensitized Animals Received CM), and SCV (Sensitized Animals Received rBMMSCs) (for
Each Group, n = 6)
C CSV CCV S SSV SCV
Total WBC
(number/mm3)
5116.67 ± 94.57 5025 ± 118.15 4841.67 ± 133.18 11,916.67 ± 166.17
+++
11,833.33 ± 125.61
+++
11,016.67 ± 153.66
+++ ** !!
Eosinophil (%) 1.1 ± 0.24 1.3 ± 0.23 1 ± 0.4 4 ± 0.56
+++
4.33 ± 0.61
+++
2.6 ± 0.24
++ * !
Neutrophil (%) 26 ± 0.84 25..66 ± 0.93 24 ± 1.24 31 ± 1.63
+
32 ± 2.44
+
29.66 ± 2.95
Lymphocyte (%) 68.66 ± 0.93 69.66 ± 0.84 70.66 ± 1.02 61 ± 1.4
++
63 ± 1.47
++
65 ± 1.09
+ *
Monocyte (%) 4.3 ± 0.46 3.6 ± 0.23 4 ± 0.48 2 ± 0.4
++
1.7 ± 0.4
++
2.3 ± 0.75
+
Statistical differences between control and different groups: +, p < 0.05; ++, p < 0.01; +++, p < 0.001. Statistical differences between SSVand SCV versus S
group: *, p < 0.05; **, p < 0.01. Statistical differences between SSVand SCV groups: !, p < 0.05; !!, p < 0.01
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diminished simultaneously (p < 0.01 to p < 0.05). No
obvious results were taken in terms of CD3+CD4+ and
CD3+CD8+ cell population between SSV and S groups
(Fig. 6).
Pre-Labeled Injected Cells Successfully Recruited into
Pulmonary Tissue
According to immunofluorescence assay, the exis-
tence of pre-labeled MSCs was further confirmed either
in non-asthmatic and peculiarly asthmatic rats that received
cells systematically. Interestingly, we also affirmed the
presence of injected cells in control non-asthmatic rats. It
seems that MSCs could potentially recruit into normal lung
tissue (Fig. 7).
DISCUSSION
In the current experiment, we evaluated the possible
modulation of rBMMSC monoculture and MSC-derived
CM on tracheal responsiveness and inflammatory process
mainly focused on total WBC count of blood and lung
lavage fluid. Additionally, the number of circulating
CD3+CD4+ and CD3+CD8+ cells were further monitored.
On account of many common features of allergic
asthma between rats and humans, allergic asthma induced
by ovalbumin was used throughout our study [29]. Con-
sidering the characteristics of induced asthmatic sensitiza-
tion, a prominent tracheal responsiveness and contractility
response to methacholine with a simultaneous increase of
total WBC population particularly eosinophil count fol-
lowed by a marked decrement in the percentages of lym-
phocyte and monocyte numbers confirmed the effective-
ness of sensitization in rats as compared to parallel controls
[8, 30, 31].
Our results revealed that the use of rBMMSCs could
improve the contractility response and tracheal responsive-
ness to methacholine in sensitized rats. Concurrently, the
total and differential WBC counts both in the blood and
lung lavage fluid nearly reached to normal state as com-
pared to control group. With regard to different cell panels
typified here, the decrement of CD3+CD8+ cells coincided
with the increase in the number of CD3+CD4+ cells in cell-
treated rats. Based on the given results, no obvious thera-
peutic effects originating from CM were also evident in
ovalbumin-induced asthmatic rats. Noticeably, neither
MSCs nor MSC-CM showed significant changes on the
measured parameters of saline-challenged rats, which were
consistent with the results of many previous studies [6]. In
line with our data, the intravenous injection of BMMSCs
attenuated the airway inflammation rate of an asthmatic
murine model [6, 14, 32]. It seems that the extensive
vascular bed, eminent production of inflammatory factors,
and various chemokines through an active dynamic of
inflamed sites, especially as seen in asthmatic lung, are
responsible for the high rate of MSC recruitment [16, 33].
Additionally, both anti-inflammatory and immune-
regulatory effects driven by MSCs have been already
documented [9]. Contradicting data were, however,
reported by different working groups, especially by Trzil
et al., that the administration of adipose-derived MSCs did
Table 2. Total and Differential Percentage ofWhite Blood Cell (WBC) Count in Lung Lavage Fluid of C (Control Group), CSV (Healthy Animals Received
CM), CCV (Healthy Animals Received rBMMSCs), S (Sensitized Animals), SSV (Sensitized Animals Received CM), and SCV (Sensitized Animals
Received rBMMSCs) (for Each Group, n = 6)
C CSV CCV S SSV SCV
Total WBC
(number/mm3)
32.5 ± 2.14 32.5 ± 2.14 30.83 ± 2.38 100 ± 2.58
+++
97.5 ± 2.5
+++
90.83 ± 1.54
+++ * !
Eosinophil (%) 5.5 ± 0.28 5.6 ± 0.4 5.4 ± 0.44 14.88 ± 0.94
+++
13 ± 1.47
+++
10 ± 1.86
+ * !
Neutrophil (%) 8 ± 0.57 8.6 ± 1.3 8 ± 0.48 14 ± 1.22
++
15.7 ± 1.83
++
10.67 ± 0.81
+ * !
Lymphocyte (%) 68.5 ± 2.85 67.62 ± 0.89 67.86 ± 2 53 ± 2.16
++
54.8 ± 2.44
++
60 ± 2.24
+ *
Monocyte (%) 15.32 ± 0.32 14.3 ± 0.48 15.66 ± 0.93 13.37 ± 0.65
+
14 ± 3
+
15.5 ± 4
*
Basophil (%) 2 ± 0.4 1.6 ± 0.48 2.3 ± 0.57 4 ± 0.69
+
3.2 ± 0.24
+
3.4 ± 0.36
+
Statistical differences between control and different groups: +, p < 0.05; ++, p < 0.01; +++, p < 0.001. Statistical differences between SSVand SCV versus S
group: *, p < 0.05. Statistical differences between SSVand SCV groups: !, p < 0.05.
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not attenuate airway inflammation on a feline model of
asthma [15]. The logical explanation for this discrepancy
could be presumably related to animal species, sensitiza-
tion method, the source, dosage, route, and time of cell
administration [34]. Also, some experiments showed that
the survival and differentiation rate might be faded at sites
of injury and inflammation [35–37]. In the current study,
an appropriate number of pre-labeled MSCs were proved
in pulmonary tissues of asthmatic rats and other groups.
Some authorities also acclaimed that a distinct post-
transplantation period must be assumed to track MSCs in
specific tissues [38, 39]. In one study, human and mouse
adipose stem cells were successfully detected 3 weeks
post-transplantation [39]. Similar to work by Ghorbani
et al., we confirmed the presence of pre-labeled cells in
injured lungs after 2 weeks [38]. As expected in the
distribution of vascular bed of the pulmonary system, we
however detected the presence of pre-labeled cells in nor-
mal non-asthmatic rats. In contrast to our result, Abreu and
other authorities revealed MSCs homing only in injured
lung tissue [11, 38]. By virtue of animal strain and species,
injection route, and recovery time after cell injection, stem
cell type and the number of injected cells, grade and type of
damaged tissue, and volume and type of cell tracker used
controversial results that have been obtained [10, 15, 40–
42].
According to the literature, various numbers of cells
ranging from 1 × 106 to 5 × 107 had been applied [43–45]
by which a systemic injection of the higher number of
human or mice MSCs into a murine model not only
regenerated pulmonary tissue but also increased adverse
effects and mortality rate because of cell-based pulmonary
Fig. 6. Flow cytometric analysis of rat peripheral mononuclear cells in different groups (a, b). The cells were stained with a panel of antibodies, including
CD3−CD4 and CD3−CD8. The percentage of mononuclear cells expressing each marker is expressed as mean ± SEM.
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embolism [42]. Fortunately, a well-tolerated situation with-
out mortality or adverse effects was observed in designated
experimental groups.
Our study did not unravel the paracrine therapeutic
effect originated by MSCs-CM. Contrary to our result, the
intravenous injection of human MSC-CM reduced apopto-
sis, oxidative stress, and inflammation in a porcine model
of myocardial infarction and finally improved tissue func-
tion following injury [17]. Concurrently, Lonescu and his
colleagues evaluated the therapeutic effect of MSC-CM on
LPS-induced lung injury. Their results showed that MSC-
CM decreased lung inflammation, pathological changes,
and lung vascular permeability [46]. It seems that the
possible reason for the ineffectiveness of systemic injection
Fig. 7. Representative fluorescent image of lung parenchyma obtained from non-sensitized and sensitized rats receiving rBMMSC-CM or rBMMSCs and
compared to control groups. As can be seen, the MSCs are labeled with CM-Dil and administrated intravenously.
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of rBMMSCs-CM on the parameters measured for this
study was a variety in secreted agents or volume used,
and the condition that the CM was harvested. On the other
hand, the secretome could easily disperse into the periph-
eral tissues and not efficiently reach injured tissue. Perhaps
injection with high volume and/or repeated doses and intra-
tracheal injection may be effective. However, further stud-
ies are suggested to evaluate the paracrine and direct effects
of MSCs from other sources during different stages of
induction of experimental asthma in rats.
The most beneficial effects of MSC administration
seen here were devoted to MSC mobilization and recruit-
ment into injured lungs through chemotaxis in response to
inflammatory agents produced in injured tissue [47]. The
prominent limitation related to our study is that the per-
centage of CD4 subpopulation, including T helper 1, 2 and
T regulatory, was not defined. Moreover, the trans-
differentiation capacity of recruited cells into pulmonary
resident cells was not investigated. In conclusion, the
results from this study showed anti-inflammatory therapeu-
tic effects following intravenous administration of
rBMMSCs on experimental sensitized rats. However, no
regenerative responses were observed post-systemic
administrations of MSC-CM.
ACKNOWLEDGMENTS
This is a report of a database from the thesis entitled
BThe effect of mesenchymal stem cells or their secretions
on tracheal responsiveness and lung inflammation in
ovalbumin-sensitized male rats^ registered in Drug Ap-
plied Research Center of Tabriz University of Medical
Sciences.
COMPLIANCE WITH ETHICAL STANDARDS
Conflict of Interest. None declared.
REFERENCES
1. Campos, H.D.S., andA.C.M. Lemos. 2009. Asthma and COPD accord-
ing to the pulmonologist. Jornal Brasileiro de Pneumologia 35(4):
301–309.
2. Neamati, A., M.H. Boskabady, N. Mahdavi-Shahri, and M. Mahmou-
dabady. 2013. The preventive effect of Brassica napus L. oil on
pathophysiological changes of respiratory system in experimental asth-
matic rat. Avicenna Journal of Phytomedicine 3(1): 56.
3. Bloemen, K., S. Verstraelen, R. Van Den Heuvel, H. Witters, I. Nelis-
sen, and G. Schoeters. 2007. The allergic cascade: review of the most
important molecules in the asthmatic lung. Immunology Letters 113(1):
6–18.
4. Ishmael, F.T. 2011. The inflammatory response in the pathogenesis of
asthma. The Journal of the American Osteopathic Association
111(11_suppl_7): S11–S17.
5. Douglas, G., B. Higgins, N. Barnes, A. Boyter, S. Burge, C. Cates, et al.
2008. British guideline on the management of asthma: a national
clinical guideline. Thorax 63(Suppl. 4): iv1–iv121.
6. Bonfield, T.L., M. Koloze, D.P. Lennon, B. Zuchowski, S.E. Yang, and
A.I. Caplan. 2010. Human mesenchymal stem cells suppress chronic
airway inflammation in themurine ovalbumin asthmamodel.American
Journal of Physiology—Lung Cellular and Molecular Physiology
299(6): L760–L770.
7. Rana Keyhanmanesh, L.P., H. Omrani, Z. Mirzamohammadi, and A.A.
Shahbazfar. 2014. The effect of single dose of thymoquinone, the main
constituents of Nigella sativa, in guinea pig model of asthma. BioIm-
pacts: BI 4(2): 75.
8. Vosooghi, S., M. Mahmoudabady, A. Neamati, and H. Aghababa.
2013. Preventive effects of hydroalcoholic extract of saffron on hema-
tological parameters of experimental asthmatic rats. Avicenna Journal
of Phytomedicine. 3(3): 279.
9. Kavanagh, H., and B. Mahon. 2011. Allogeneic mesenchymal stem
cells prevent allergic airway inflammation by inducing murine regula-
tory T cells. Allergy 66(4): 523–531.
10. Abreu, S.C., M.A. Antunes, T. Maron-Gutierrez, F.F. Cruz, D.S.
Ornellas, A.L. Silva, et al. 2013. Bone marrow mononuclear cell
therapy in experimental allergic asthma: intratracheal versus intrave-
nous administration. Respiratory Physiology & Neurobiology 185(3):
615–624.
11. Abreu, S.C., M.A. Antunes, J.C. de Castro, M.V. de Oliveira, E.
Bandeira, D.S. Ornellas, et al. 2013. Bone marrow-derived mononu-
clear cells vs. mesenchymal stromal cells in experimental allergic
asthma. Respiratory Physiology & Neurobiology 187(2): 190–198.
12. da Silva Meirelles, L., P.C. Chagastelles, and N.B. Nardi. 2006.
Mesenchymal stem cells reside in virtually all post-natal organs and
tissues. Journal of Cell Science 119(11): 2204–2213.
13. Bydlowski, S.P., A.A. Debes, L.M. Maselli, and F.L. Janz. 2009.
Características biológicas das células-tronco mesenquimais. Revista
Brasileira de Hematologia e Hemoterapia 31(supl 1): 25–35.
14. Goodwin, M., V. Sueblinvong, P. Eisenhauer, N.P. Ziats, L. LeClair,
M.E. Poynter, et al. 2011. Bonemarrow‐derivedmesenchymal stromal
cells inhibit Th2‐mediated allergic airways inflammation in mice.
Stem Cells 29(7): 1137–1148.
15. Trzil, J.E., I. Masseau, T.L. Webb, C.H. Chang, J.R. Dodam, L.A.
Cohn, et al. 2014. Long‐term evaluation of mesenchymal stem cell
therapy in a feline model of chronic allergic asthma. Clinical and
Experimental Allergy. 44(12): 1546–1557.
16. Kyurkchiev, D., I. Bochev, E. Ivanova-Todorova, M. Mourdjeva, T.
Oreshkova, K. Belemezova, et al. 2014. Secretion of immunoregula-
tory cytokines by mesenchymal stem cells. World Journal of Stem
Cells 6(5): 552.
17. Timmers, L., S.K. Lim, I.E. Hoefer, F. Arslan, R.C. Lai, A.A. van
Oorschot, et al. 2011. Human mesenchymal stem cell-conditioned
medium improves cardiac function following myocardial infarction.
Stem Cell Research 6(3): 206–214.
18. Rahbarghazi, R., S.M. Nassiri, P. Khazraiinia, A.-M. Kajbafzadeh,
S.H. Ahmadi, E. Mohammadi, et al. 2012. Juxtacrine and paracrine
interactions of rat marrow-derived mesenchymal stem cells, muscle-
derived satellite cells, and neonatal cardiomyocytes with endothelial
cells in angiogenesis dynamics. Stem Cells and Development 22(6):
855–865.
1970 Ahmadi, Rahbarghazi, Soltani, Aslani, and Keyhanmanesh
19. Rahbarghazi, R., S.M. Nassiri, S.H. Ahmadi, E. Mohammadi, S.
Rabbani, A. Araghi, et al. 2014. Dynamic induction of pro-
angiogenic milieu after transplantation of marrow-derived mesenchy-
mal stem cells in experimental myocardial infarction. International
Journal of Cardiology 173(3): 453–466.
20. Mao, Q., C.-X. Lin, X.-L. Liang, J.-S. Gao, and B. Xu. 2013. Mesen-
chymal stem cells overexpressing integrin-linked kinase attenuate
cardiac fibroblast proliferation and collagen synthesis through para-
crine actions. Molecular Medicine Reports 7(5): 1617–1623.
21. Schuster, M., T. Tschernig, N. Krug, and R. Pabst. 2000. Lymphocytes
migrate from the blood into the bronchoalveolar lavage and lung
parenchyma in the asthma model of the brown Norway rat. American
Journal of Respiratory and Critical Care Medicine 161(2): 558–566.
22. Khazdair, M.R., M.H. Boskabady, A. Tabatabaee, M. Hosseini, and
M. Abbasnejad. 2013. Effect of inhaled fluticasone and salmeterol on
tracheal responsiveness and lung inflammation: influence of adminis-
tration time and allergen-free period. Indian Journal of Medical Sci-
ences 67(3): 78.
23. Gholamnezhad Z, Boskabady MH, Khazdair MR, Hosseini M,
AbbasnejadM. 2014. Effect of fluticasone and salmeterol on tracheal
responsiveness to ovalbumin and lung inflammation, administrated
during and after sensitization. The Scientific World Journal. 2014.
24. Hajighahramani, S., and N. Vesal. 2007. Evaluation of several drug
combinations for intraperitoneal anaesthesia in adult male rats. Iranian
Journal of Veterinary Research. 8(2): 106–115.
25. Chang, Y.-N., C.-H. Wang, C.-C. Wu, and H.-W. Wang. 2012. Effects
of bupivacaine on the isolated rat tracheal smooth muscle. Journal of
Experimental and Clinical Medicine 4(1): 62–65.
26. Keyhanmanesh, R., H. Bagban, H. Nazemiyeh, F.M. Bavil, M.R.
Alipour, and M. Ahmady. 2013. The relaxant effects of different
methanolic fractions of Nigella sativa on guinea pig tracheal chains.
Iranian Journal of Basic Medical Sciences 16(2): 123.
27. Boskabady, M.H., R. Keyhanmanesh, S. Khamneh, and M.A. Ebra-
himi. 2011. The effect of Nigella sativa extract on tracheal respon-
siveness and lung inflammation in ovalbumin-sensitized guinea pigs.
Clinics 66(5): 879–887.
28. Mahmoudabady, M., A. Neamati, S. Vosooghi, and H. Aghababa.
2013. Hydroalcoholic extract of Crocus sativus effects on bronchial
inflammatory cells in ovalbumin sensitized rats. Avicenna Journal of
Phytomedicine. 3(4): 356–363.
29. Kucharewicz, I., I. Kasacka, D. Pawlak, A. Tankiewicz-Kwedlo, B.
Mroczko, W. Buczko, et al. 2008. The concentration of kynurenine in
rat model of asthma. Folia Histochemica et Cytobiologica 46(2): 199–
8.
30. Pejman, L., H. Omrani, Z. Mirzamohammadi, A.A. Shahbazfar, M.
Khalili, and R. Keyhanmanesh. 2014. The effect of adenosine A2A
and A2B antagonists on tracheal responsiveness, serum levels of
cytokines and lung inflammation in guinea pig model of asthma.
Advanced Pharmaceutical Bulletin 4(2): 131.
31. Bayrami, G., and M. Boskabady. 2012. The potential effect of the
extract of Crocus sativus and safranal on the total and differential
white blood cells of ovalbumin-sensitized guinea pigs. Research in
Pharmaceutical Sciences 7(4): 249.
32. Nemeth, K., A. Keane-Myers, J.M. Brown, D.D. Metcalfe, J.D. Gor-
ham, V.G. Bundoc, et al. 2010. Bone marrow stromal cells use TGF-β
to suppress allergic responses in a mouse model of ragweed-induced
asthma. Proceedings of the National Academy of Sciences 107(12):
5652–5657.
33. Zhao, M.M., J.Z. Cui, Y. Cui, R. Li, Y.X. Tian, S.X. Song, et al. 2013.
Therapeutic effect of exogenous bone marrow-derived mesenchymal
stem cell transplantation on silicosis via paracrine mechanisms in rats.
Molecular Medicine Reports 8(3): 741–746.
34. Rangwala, R., R. Leone, Y.C. Chang, L.A. Fecher, L.M. Schuchter, A.
Kramer, et al. 2014. Phase I trial of hydroxychloroquine with dose-
intense temozolomide in patients with advanced solid tumors and
melanoma. Autophagy 10(8): 1369–1379.
35. Gallina, C., V. Turinetto, and C. Giachino. 2015. A new paradigm in
cardiac regeneration: the mesenchymal stem cell secretome. Stem
Cells International 2015(765846): 765846.
36. Cantinieaux, D., R. Quertainmont, S. Blacher, L. Rossi, T. Wanet, A.
Noël, et al. 2013. Conditioned medium from bone marrow-derived
mesenchymal stem cells improves recovery after spinal cord injury in
rats: an original strategy to avoid cell transplantation. PloS One 8(8):
e69515.
37. Linero, I., and O. Chaparro. 2014. Paracrine effect of mesenchymal
stem cells derived from human adipose tissue in bone regeneration.
PloS One 9(9): e107001.
38. Ghorbani, A., A. Feizpour, M. Hashemzahi, L. Gholami, M. Hosseini,
M. Soukhtanloo, et al. 2014. The effect of adipose derived stromal
cells on oxidative stress level, lung emphysema and white blood cells
of guinea pigs model of chronic obstructive pulmonary disease. Daru
22(1): 22–26.
39. Schweitzer, K.S., B.H. Johnstone, J. Garrison, N.I. Rush, S. Cooper,
D.O. Traktuev, et al. 2011. Adipose stem cell treatment in mice
attenuates lung and systemic injury induced by cigarette smoking.
American Journal of Respiratory and Critical Care Medicine
183(2): 215–225.
40. Herzog, E.L., J. Van Arnam, B. Hu, and D.S. Krause. 2006. Threshold
of lung injury required for the appearance of marrow‐derived lung
epithelia. Stem Cells 24(8): 1986–1992.
41. Abe, S., C. Boyer, X. Liu, F.Q. Wen, T. Kobayashi, Q. Fang, et al.
2004. Cells derived from the circulation contribute to the repair of lung
injury. American Journal of Respiratory and Critical Care Medicine
170(11): 1158–1163.
42. Lee, R.H., A.A. Pulin, M.J. Seo, D.J. Kota, J. Ylostalo, B.L. Larson,
et al. 2009. Intravenous hMSCs improvemyocardial infarction in mice
because cells embolized in lung are activated to secrete the anti-
inflammatory protein TSG-6. Cell Stem Cell 5(1): 54–63.
43. Shigemura, N., M. Okumura, S. Mizuno, Y. Imanishi, T. Nakamura,
and Y. Sawa. 2006. Autologous transplantation of adipose tissue‐
derived stromal cells ameliorates pulmonary emphysema. American
Journal of Transplantation 6(11): 2592–2600.
44. Ishizawa, K., H. Kubo, M. Yamada, S. Kobayashi, M. Numasaki, S.
Ueda, et al. 2004. Bone marrow-derived cells contribute to lung
regeneration after elastase-induced pulmonary emphysema. FEBS
Letters 556(1): 249–252.
45. Luan, Y., X. Zhang, F. Kong, G.-H. Cheng, T.-G. Qi, and Z.-H. Zhang.
2012. Mesenchymal stem cell prevention of vascular remodeling in
high flow-induced pulmonary hypertension through a paracrine mech-
anism. International Immunopharmacology 14(4): 432–437.
46. Ionescu, L., R.N. Byrne, T. van Haaften, A. Vadivel, R.S. Alphonse,
G.J. Rey-Parra, et al. 2012. Stem cell conditioned medium improves
acute lung injury in mice: in vivo evidence for stem cell paracrine
action. American Journal of Physiology—Lung Cellular and Molecu-
lar Physiology 303(11): L967–L977.
47. Conese M, Piro D, Carbone A, Castellani S, Di Gioia S. 2014.
Hematopoietic and mesenchymal stem cells for the treatment of
chronic respiratory diseases: role of plasticity and heterogeneity.
The Scientific World Journal. 2014.
1971Contributory Anti-Inflammatory Effects of Mesenchymal Stem Cells
